R&D expense · 2011–2025
Alnylam Pharmaceuticals R&D expense
$1.3B+17.2% · FY2025
Alnylam Pharmaceuticals (ALNY) reported $1.3B in R&D expense for fiscal 2025, +17.2% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $1.3B | +17.2% | Open → |
| FY20242024-12-31 | $1.1B | +12.1% | Open → |
| FY20232023-12-31 | $1.0B | +13.7% | Open → |
| FY20222022-12-31 | $883M | +11.5% | Open → |
| FY20212021-12-31 | $792M | +21.0% | Open → |
| FY20202020-12-31 | $655M | −0.0% | Open → |
| FY20192019-12-31 | $655M | +29.6% | Open → |
| FY20182018-12-31 | $505M | +29.4% | Open → |
| FY20172017-12-31 | $391M | +2.2% | Open → |
| FY20162016-12-31 | $382M | +38.3% | Open → |
| FY20152015-12-31 | $276M | +45.3% | Open → |
| FY20142014-12-31 | $190M | +68.4% | Open → |
| FY20132013-12-31 | $113M | +30.5% | Open → |
| FY20122012-12-31 | $86.6M | −12.8% | Open → |
| FY20112011-12-31 | $99.3M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +20.3%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Alnylam Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/alnylam-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Alnylam Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/alnylam-pharmaceuticals/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-alnylam-pharmaceuticals-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Alnylam Pharmaceuticals R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/alnylam-pharmaceuticals/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-007497 · February 12, 2026
{{cite web |title=Alnylam Pharmaceuticals R&D expense — 10-K (0001628280-26-007497) |url=https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.